Novo Nordisk's Pipeline: What Comes After Wegovy

Semaglutide has carried Novo Nordisk for most of a decade. In 2025 it accounted for roughly two thirds of company sales. That is a great position and a fragile one, and the obvious question — from investors, from doctors, and from people already taking these medicines — is what comes next.

The short answer: two new semaglutide formats already launched in 2026, one major combination drug awaiting an FDA decision, a next-generation single molecule heading into large trials, and a handful of expensive disappointments along the way.

This is a guide to what is actually in the pipeline, written in plain English. It is not medical advice, and nothing here should be read as a recommendation. Investigational drugs are not available outside clinical trials, and approval timelines slip all the time.

What has Novo Nordisk already launched in 2026?

Two things, both semaglutide, both aimed at closing gaps in the existing lineup.

The Wegovy pill (oral semaglutide 25 mg). The FDA approved it on December 22, 2025 and Novo Nordisk launched it on January 5, 2026. It is the first oral GLP-1 approved for weight management anywhere. In the OASIS 4 trial it produced an average of 16.6% weight loss at 64 weeks among participants who stayed on treatment, against 2.7% on placebo, and 34.4% of them lost 20% or more of body weight. Counting everyone randomized regardless of whether they stayed on the drug, average weight loss was about 14% [1][18]. The label also includes cardiovascular risk reduction.

Launch pricing in the cash-pay channel started at $149 a month for the 1.5 mg starting dose, rising to $199 for 4 mg and $299 for the 9 mg and 25 mg doses, available at more than 70,000 pharmacies and through telehealth partners [7].

The uptake has been the strongest part of Novo Nordisk’s 2026. The company reported that weekly US prescriptions exceeded 265,000 for the week ending July 17, 2026 and that cumulative prescriptions passed 5 million, calling it the strongest GLP-1 volume launch in US history [1]. Read those figures carefully: they come from Novo Nordisk’s own partner-reported paid claims. IQVIA, which the rest of the industry tracks, counted about 170,000 weekly prescriptions for the pill that same week and about 183,000 in the week reported on September 11, 2026 [19]. Both series agree on the direction; they disagree on the level.

Novo Nordisk also says more than 80% of new prescriptions for the pill are going to people new to the GLP-1 class, which would mean the pill is expanding the market rather than simply cannibalizing injections [1]. That is a company figure about new starts, not a share of all prescriptions. IQVIA’s own independent read was similar in direction but lower: around two thirds of early volume from people new to any GLP-1 [16].

Wegovy HD (semaglutide injection 7.2 mg). Approved March 19, 2026 and launched in April, this is a higher weekly dose for people who have already tolerated 2.4 mg for at least four weeks. In the STEP UP trial it produced 20.7% mean weight loss, with roughly one in three participants losing 25% or more of body weight [8]. The FDA reviewed it under a Commissioner’s National Priority Voucher, which shortened the process.

There is also a rebrand worth knowing about. In February 2026 the FDA approved “Ozempic” as the name for a reformulated oral semaglutide for type 2 diabetes at 1.5 mg, 4 mg and 9 mg. Novo Nordisk launched the Ozempic pill in May 2026 and is retiring the Rybelsus name in the United States [9]. Same molecule, smaller tablet, new coating, much better-known brand.

What is CagriSema and when might it be approved?

CagriSema is Novo Nordisk’s lead next-generation obesity candidate and the single biggest swing factor in its near-term pipeline.

It is a weekly injection combining two things: semaglutide, the familiar GLP-1 receptor agonist, and cagrilintide, a long-acting analog of amylin. Amylin is a hormone released alongside insulin that helps signal fullness and slows how fast the stomach empties. The idea is that hitting two different satiety pathways works better than hitting one.

Novo Nordisk submitted CagriSema to the FDA in December 2025, based on the REDEFINE 1 trial in 3,417 adults with obesity or overweight plus a comorbidity, and REDEFINE 2 in 1,206 adults with type 2 diabetes. A US decision is expected in the fourth quarter of 2026 [3][1].

The results have been strong in absolute terms and disappointing in relative terms. In REDEFINE 1, about 92% of participants lost at least 5% of body weight, against 31.5% on placebo [3]. But on February 23, 2026, Novo Nordisk reported the REDEFINE 4 head-to-head trial against tirzepatide: CagriSema produced 23% mean weight loss at 84 weeks, tirzepatide 25.5%, and CagriSema failed its non-inferiority endpoint. The stock fell more than 15% [5][4].

In the diabetes program, the REIMAGINE 4 head-to-head told a similar story: CagriSema matched tirzepatide 15 mg on weight loss (15.2% versus 15.8% in the adherent analysis) but not on blood sugar control (1.9 versus 2.2 percentage points of HbA1c reduction) [1].

Novo Nordisk’s public position is that the world became “obsessed with one number.” CEO Mike Doustdar has argued that combining the extensive evidence base behind semaglutide with a new mechanism gives “the best of the two worlds” [14]. A higher-dose version, CagriSema 2.4 mg / 7.2 mg, entered phase 3 in 2026 with a readout expected in the first half of 2028 [1].

What is zenagamtide, and why was it called amycretin?

Zenagamtide is the same drug that was called amycretin in earlier coverage. Novo Nordisk renamed it; if you search the old name you will find the same molecule.

Where CagriSema is two molecules in one syringe, zenagamtide is a single peptide that activates both the GLP-1 and amylin receptors. It exists in both injectable and oral forms, which is unusual and strategically useful.

The phase 2 data in type 2 diabetes, presented at the American Diabetes Association meeting in June 2026, showed up to 14.6% weight loss at week 36 on the 40 mg dose against 2.1% on placebo, plus HbA1c reductions of up to 1.71 percentage points [6].

Novo Nordisk started the phase 3 obesity program, called AMAZE, in the first quarter of 2026 and planned a phase 3 type 2 diabetes program in the second half of 2026 [6]. It also began two large trials in 2026: HF-POLARIS, an event-driven phase 3 trial in about 5,600 people with heart failure with preserved or mildly reduced ejection fraction plus obesity, reading out in the second half of 2029; and AMAZE 8, comparing zenagamtide to semaglutide over two years, reading out in the first half of 2029 [1].

Doustdar has repeatedly named zenagamtide first when asked why investors should be confident in the pipeline.

What else is in the obesity and metabolic pipeline?

Cagrilintide on its own. The amylin analog is being tested as a standalone treatment. Doustdar has framed it as an option with lower weight-loss efficacy but better tolerability, for people who would trade some weight loss for less nausea and vomiting [14]. A high-dose phase 3 program was planned to start in the fourth quarter of 2026 [1].

Triple agonists. Novo Nordisk has two. UBT251, licensed from United Laboratories, hits GLP-1, GIP and glucagon; it completed a phase 2 trial in China and started another in people with overweight or obesity plus type 2 diabetes, reading out at the end of 2027. A second triple agonist, referred to simply as “Triple,” targets amylin alongside GIP and GLP-1 and entered a phase 2 dose-finding trial in around 230 people, reading out in the first quarter of 2027 [1].

Efruxifermin. Acquired when Novo Nordisk bought Akero Therapeutics for up to $5.2 billion in a deal announced October 9, 2025, this is a once-weekly engineered FGF21 analog for metabolic dysfunction-associated steatohepatitis, or MASH — the serious form of fatty liver disease [12]. Phase 3 safety results from the SYNCHRONY Real-World study were expected in the fourth quarter of 2026 [1].

Semaglutide in MASH. Separately from efruxifermin, semaglutide 2.4 mg was approved for MASH in the United States in 2025 and in Japan and the United Kingdom in 2026, based on the ESSENCE trial. Novo Nordisk has also filed to add MASH data to the Wegovy pill label, with a US decision expected in the first quarter of 2027 [1].

Oral biologics. In February 2026 Novo Nordisk signed a deal worth up to $2.1 billion with Boston-based Vivtex to develop next-generation oral formulations for obesity, diabetes and metabolic disease [13]. This is the company defending the one lane where it is clearly ahead of Eli Lilly.

What is Novo Nordisk working on outside obesity and diabetes?

Less than it used to be, deliberately.

At the J.P. Morgan Healthcare Conference in January 2026, Doustdar said the company would use diabetes and obesity as a “starting point” for adjacent diseases rather than “rushing in” to new areas, describing it as “taking the company back to the DNA we have” [14].

What remains:

• Denecimig (Mim8) for hemophilia A, with US and EU decisions expected in the third quarter of 2026 and a China submission filed in 2026 [1]
• Etavopivat for sickle cell disease, with US and EU submissions expected in the fourth quarter of 2026 [1]
• Sogroya label expansions for children with short stature, with a Turner syndrome decision expected in the fourth quarter of 2026 in the United States [1]
• Next-generation insulins, including IcoSema and the once-weekly insulin Awiqli, which was approved in the United States in 2026 [1][2]
• Ziltivekimab after heart attack (ARTEMIS), reading out in the first half of 2027 — the only surviving phase 3, after Novo Nordisk halted the heart failure trials HERMES and ATHENA for futility on September 4, 2026 on an independent data monitoring committee recommendation, leaving three of the four phase 3 cardiovascular studies negative or discontinued [11][22][23] (updated 2026-09-14)
• Early-stage programs including an oral NLRP3 inhibitor for inflammation in cardiometabolic disease, reading out in the second half of 2027 [1]

Which Novo Nordisk programs have failed?

Three notable ones in under a year, and it is worth being straightforward about them.

Alzheimer’s disease. The evoke and evoke+ phase 3 trials enrolled 3,808 adults aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s disease and confirmed amyloid. On November 24, 2025, Novo Nordisk reported that oral semaglutide did not slow disease progression on the primary measure compared with placebo. Alzheimer’s-related biomarkers improved, but that did not translate into a clinical benefit, and the one-year extension was discontinued [10]. The results were later published in The Lancet.

Cardiovascular disease with ziltivekimab. The ZEUS trial enrolled more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. Reported July 31, 2026, the drug lowered inflammatory markers as designed but produced a hazard ratio of 0.99 for major adverse cardiovascular events — effectively no difference from placebo. Serious infections were more common on treatment, consistent with the drug class [11].

Monlunabant. Novo Nordisk terminated development of this oral obesity candidate in the second quarter of 2026 for portfolio reasons, taking a DKK 4.0 billion non-cash impairment within DKK 6.3 billion of total pipeline write-downs that quarter [1].

Failures like these are normal in drug development. What made them sting is their timing: they landed in the same window as a leadership change, a restructuring and a share price collapse, and they removed exactly the “semaglutide is bigger than weight loss” story the company had been telling.

When do Novo Nordisk’s patents expire?

This is a real deadline, not a theoretical one, and it arrived earlier outside the United States than most people expect.

In the United States, semaglutide protection runs into the early 2030s — the key composition patent runs to 2032. That is the core of the business and it is not immediately at risk, though Novo Nordisk has been defending it in court. It sued Cipla over a generic Ozempic application, and sued Hims & Hers in February 2026 over the oral-delivery patent US 8,129,343. The Hims & Hers case did not go to a ruling: Novo Nordisk voluntarily dismissed it without prejudice on March 9, 2026, and the two companies announced a commercial arrangement instead, under which Hims & Hers sells FDA-approved Ozempic and Wegovy and stops advertising compounded GLP-1 products [1][20].

Outside the United States, a first wave of expiries hit in 2026: Canada in January, then India, China and Brazil in March, plus Mexico, Turkey, Saudi Arabia and South Africa [15][16]. Together those markets cover roughly 40% of the world’s population. Generic semaglutide launched in India during the first quarter of 2026, and Novo Nordisk named the expiries as a specific drag on its 2026 International Operations outlook [2].

In Europe, Sandoz filed at the Unified Patent Court in June 2026 seeking to revoke a Novo Nordisk patent covering the 1 mg dose of semaglutide for diabetes in 18 EU countries [1].

This is precisely why the pipeline matters so much. CagriSema, zenagamtide and the oral formats are the company’s answer to a molecule that will eventually be cheap everywhere.

What should you watch next?

A few dated milestones sit close together:

• September 21, 2026 — Novo Nordisk’s Capital Markets Day in London, the first under Doustdar, where the company said it would give a full review of strategy and financial targets. He has publicly teased earlier-stage assets not yet disclosed [17][14]. The company previewed it on September 14 by rebranding: it now uses the single name “Novo” day to day, under the line “Lasting Health Starts Now,” though Novo Nordisk A/S remains the legal name and no product brand changes [21].
• Fourth quarter 2026 — expected FDA decisions on CagriSema for weight management and on oral semaglutide 25 mg in diabetes, plus expected phase 3 safety results for efruxifermin.
• First half 2027 — the ARTEMIS readout for ziltivekimab, now the only remaining phase 3 after the HERMES and ATHENA futility halts of September 4, 2026 [22], and the expected FDA decision on adding MASH data to the Wegovy pill label. (updated 2026-09-14)
• 2028 and 2029 — readouts for high-dose CagriSema and for zenagamtide’s large obesity, diabetes and heart failure trials.

A last word on how to read pipeline news: a drug that is “in phase 3” is not an available medicine, and a strong topline number in a press release is not the same as an approved label. If you are considering a GLP-1 medicine now, the conversation to have is with a healthcare provider about the ones that are actually approved and covered for you.

Sources

1. Novo Nordisk financial report for 1 January to 30 June 2026 (Form 6-K) — Novo Nordisk A/S via SEC EDGAR, August 4, 2026
2. Novo Nordisk financial report for 1 January to 31 December 2025 (Form 6-K) — Novo Nordisk A/S via SEC EDGAR, February 3, 2026
3. Novo Nordisk submits NDA to FDA for CagriSema — Pharmaceutical Executive, December 2025
4. Novo’s CagriSema falls to Lilly’s Zepbound in daring head-to-head test — BioSpace, February 23, 2026
5. Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly’s in trial — CNBC, February 23, 2026
6. Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes — Novo Nordisk via PR Newswire, June 2026
7. Novo’s Wegovy pill makes US debut, with starter dose launching at $149 per month — Fierce Pharma, January 5, 2026
8. Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss — Novo Nordisk via GlobeNewswire, March 19, 2026
9. Novo to launch Ozempic pill for diabetes in second quarter of 2026 — Reuters, February 4, 2026
10. Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression — Novo Nordisk via GlobeNewswire, November 24, 2025
11. Novo Nordisk provides update on the ZEUS phase 3 trial — Novo Nordisk via GlobeNewswire, July 31, 2026
12. Novo Nordisk to acquire Akero Therapeutics — Novo Nordisk via GlobeNewswire, October 9, 2025
13. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs — Reuters, February 25, 2026
14. ‘I’m a lot more optimistic today’: Mike Doustdar on his first year as Novo Nordisk CEO — Fierce Pharma, June 11, 2026
15. Looming GLP-1 drug patent expirations draw generics firms — Chemical & Engineering News, December 9, 2025
16. Your questions answered: off-patent semaglutide in 2026 — IQVIA, April 2026
17. Novo Nordisk Capital Markets Day 2026 — Novo Nordisk A/S
18. Novo Nordisk’s phase 3 OASIS 4 analyses highlight cardiometabolic benefits of oral semaglutide 25 mg — Applied Clinical Trials, August 8, 2026
19. The oral GLP-1 tracker: Novo’s Wegovy pill vs Lilly’s Foundayo — Fierce Pharma, September 11, 2026
20. Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs — CNBC, March 9, 2026
21. Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture — Novo Nordisk via GlobeNewswire, September 14, 2026
22. Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation — STAT News, September 7, 2026
23. Novo Nordisk cans two more trials of IL-6 heart drug for futility — Endpoints News, September 7, 2026